Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma

Activating BRAF mutations occurs in 50–60% of malignant melanomas. Although initially treatable, the development of resistance to BRAF-targeted therapies (BRAFi) is a major challenge and limits their efficacy. We have previously shown that the BRAF(V600E) signaling pathway mediates the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Uebel, Anne, Kewitz-Hempel, Stefanie, Willscher, Edith, Gebhardt, Kathleen, Sunderkötter, Cord, Gerloff, Dennis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916477/
https://www.ncbi.nlm.nih.gov/pubmed/36768289
http://dx.doi.org/10.3390/ijms24031963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916477/
https://www.ncbi.nlm.nih.gov/pubmed/36768289
http://dx.doi.org/10.3390/ijms24031963

Ejemplares similares